NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free ADIL Stock Alerts $1.34 -0.06 (-3.93%) (As of 02:23 PM ET) Add Compare Share Share Today's Range$1.31▼$1.4350-Day Range$0.83▼$3.2652-Week Range$0.77▼$14.00Volume72,197 shsAverage Volume4.05 million shsMarket Capitalization$2.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Adial Pharmaceuticals alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Adial Pharmaceuticals Stock (NASDAQ:ADIL)Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Read More ADIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADIL Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 275.8% in MarchMarch 27, 2024 | americanbankingnews.comAdial Pharmaceuticals (ADIL) Scheduled to Post Quarterly Earnings on ThursdayMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 20, 2024 | americanbankingnews.comQ4 2023 Earnings Estimate for Adial Pharmaceuticals, Inc. Issued By Litchfield Hills Research (NASDAQ:ADIL)March 20, 2024 | americanbankingnews.comAdial Pharmaceuticals, Inc. Expected to Post Q1 2025 Earnings of ($0.39) Per Share (NASDAQ:ADIL)March 19, 2024 | investing.comAdial Pharmaceuticals Inc (ADIL)March 16, 2024 | finance.yahoo.comMASI Apr 2024 120.000 callMarch 16, 2024 | finance.yahoo.comMASI Apr 2024 125.000 putMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 11, 2024 | benzinga.comPeering Into Adial Pharmaceuticals's Recent Short InterestMarch 1, 2024 | globenewswire.comAdial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsMarch 1, 2024 | investing.comAdial Pharmaceuticals secures new patent for AD04 drugFebruary 28, 2024 | msn.comWhy Adial Pharmaceuticals Stock Is Blasting OffFebruary 28, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 28, 2024 | finance.yahoo.comEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use DisorderFebruary 28, 2024 | globenewswire.comAdial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 15, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc.: Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20February 15, 2024 | finance.yahoo.comAdial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20February 13, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark OfficeFebruary 13, 2024 | marketwatch.comAdial Pharma Shares Rise 26% After Patent Notice of Allowance for AD04February 13, 2024 | msn.comEXCLUSIVE: Adial Pharmaceuticals Announces New US Patent Covering Its Molecular Genetic Diagnosing For Alcohol, Drug DependenceFebruary 13, 2024 | finance.yahoo.comAdial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark OfficeJanuary 18, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Announces Appointment of Tony Goodman as Chief Operating OfficerJanuary 18, 2024 | markets.businessinsider.comAdial Pharmaceuticals Names Director Tony Goodman As Chief Operating OfficerJanuary 12, 2024 | msn.comAdial Pharmaceuticals files for $100M mixed shelfDecember 20, 2023 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Receives Final Reimbursement Payment from AdovateDecember 20, 2023 | finance.yahoo.comAdial Pharmaceuticals Receives Final Reimbursement Payment from AdovateSee More Headlines Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-332.86% Return on Assets-212.05% Debt Debt-to-Equity RatioN/A Current Ratio2.15 Quick Ratio2.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.17 per share Price / Book0.44Miscellaneous Outstanding Shares1,660,000Free Float1,422,000Market Cap$2.32 million OptionableNo Data Beta1.52 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Cary John Claiborne MBA (Age 64)CEO, President & Director Comp: $415.08kMr. Joseph A. M. Truluck M.B.A. (Age 46)MBA, CFO, Treasurer & Secretary Comp: $279.7kMr. Tony Goodman (Age 60)COO & Director Comp: $59kDr. Bankole A. Johnson DSc (Age 64)FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer Comp: $375kMr. John R. Martin J.D.General CounselMr. Alex LugovoyChief Business OfficerDr. Jack W. Reich Ph.D. (Age 75)Head of Regulatory Comp: $17.01kMr. Mark H. PeikinChief Strategy Officer & Chief Development OfficerMs. Catherine FratilaControllerMore ExecutivesKey CompetitorsPanbela TherapeuticsNASDAQ:PBLALucy Scientific DiscoveryNASDAQ:LSDICohBarNASDAQ:CWBRCNS PharmaceuticalsNASDAQ:CNSPQualigen TherapeuticsNASDAQ:QLGNView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 159,000 shares on 2/13/2024Ownership: 9.578%Kevin SchuylerBought 700 shares on 9/29/2023Total: $1,918.00 ($2.74/share)View All Insider TransactionsView All Institutional Transactions ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed in 2024? Adial Pharmaceuticals' stock was trading at $1.86 at the beginning of the year. Since then, ADIL stock has decreased by 27.7% and is now trading at $1.3450. View the best growth stocks for 2024 here. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 105,600 shares, an increase of 275.8% from the February 29th total of 28,100 shares. Based on an average trading volume of 3,820,000 shares, the short-interest ratio is currently 0.0 days. Approximately 7.0% of the shares of the stock are sold short. View Adial Pharmaceuticals' Short Interest. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) released its quarterly earnings results on Wednesday, August, 11th. The company reported ($6.25) EPS for the quarter, missing analysts' consensus estimates of ($5.00) by $1.25. When did Adial Pharmaceuticals' stock split? Shares of Adial Pharmaceuticals reverse split on the morning of Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman, Kevin Schuyler and William B Stilley III. View institutional ownership trends. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADIL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeAI to Meet the Same Fate as EVs? Porter & CompanyGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.